Skip to main content

Table 1 Patient characteristics

From: Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

  

Trifluridine/tipiracil plus bevacizumab group

Trifluridine/tipiracil monotherapy group

N = 60

%

N = 66

%

Age

Median (range)

60 (23–79)

 

65 (30–80)

 

≥65 years old

19

31.7

34

51.5

Gender

Male

35

58.3

42

63.6

ECOG PS

0

35

58.3

42

63.6

1

24

40.0

21

31.8

2

1

1.7

3

4.5

Primary location

Right

11

18.3

10

15.2

Left

49

81.7

56

84.8

Number of metastatic organs

1

6

10.0

13

19.7

2

26

43.3

39

59.1

≥3

28

46.7

14

21.2

Time from start of first-line chemotherapy

< 18 months

22

36.7

23

34.8

≥18 months

38

63.3

43

65.2

Time from prior bevacizumab

≤1 month

34

56.7

33

50.0

> 1 month or no prior bevacizumab

26

43.3

33

50.0

Number of prior regimens

1

4

6.7

2

3.0

2

29

48.3

33

50.0

3

15

25.0

16

24.2

≥4

12

20.0

15

22.7

Prior chemotherapy agents

Fluoropyrimidine

60

100

66

100

Irinotecan

60

100

66

100

Oxaliplatin

60

100

66

100

Angiogenesis inhibitors

58

96.7

61

92.4

Anti-EGFR antibodies

27

45.0

27

40.9

RAS status

Wild-type

28

46.7

30

45.5

Mutant

32

53.3

36

54.5

BRAF status

Wild-type

52

86.7

52

78.8

V600E mutant

1

1.7

4

6.1

Non-V600E mutant

2

3.3

0

0

Unknown

5

8.3

10

15.2

MSI status

MSS

53

88.3

51

77.3

Unknown

7

11.7

15

22.7

  1. ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, MSS microsatellite stable